
## Takashi Sozu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9875268/publications.pdf Version: 2024-02-01



TAKASHI SOZU

#	Article	IF	CITATIONS
1	Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?. BMC Medical Research Methodology, 2014, 14, 30.	3.1	240
2	Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage <scp>II</scp> and <scp>III</scp> thymic epithelial tumors: The <scp>J</scp> apanese <scp>A</scp> ssociation for <scp>R</scp> esearch on the <scp>T</scp> hymus <scp>D</scp> atabase <scp>S</scp> tudy. Cancer, 2015, 121, 1008-1016.	4.1	106
3	Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. Journal of the National Cancer Institute, 2018, 110, 141-148.	6.3	97
4	Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. American Heart Journal, 2012, 163, 191-199.e1.	2.7	78
5	Effective number of subjects and number of raters for inter-rater reliability studies. Statistics in Medicine, 2006, 25, 1547-1560.	1.6	68
6	Impact of Donor Age on Recipient Survival in Adult-to-Adult Living-donor Liver Transplantation. Annals of Surgery, 2018, 267, 1126-1133.	4.2	63
7	Sample size determination in clinical trials with multiple coâ€primary binary endpoints. Statistics in Medicine, 2010, 29, 2169-2179.	1.6	56
8	Association between epithelialâ€mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma. Cancer Medicine, 2015, 4, 1853-1862.	2.8	50
9	Validation study of the Short Time Exposure (STE) test to assess the eye irritation potential of chemicals. Toxicology in Vitro, 2011, 25, 796-809.	2.4	49
10	A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymomaâ€. European Journal of Cardio-thoracic Surgery, 2015, 47, 602-607.	1.4	49
11	Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: The Japanese Aortic Stenosis Study (JASS) Retrospective Analysis. Hypertension Research, 2010, 33, 269-274.	2.7	33
12	Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints. Journal of Biopharmaceutical Statistics, 2011, 21, 650-668.	0.8	33
13	A convenient formula for sample size calculations in clinical trials with multiple coâ€primary continuous endpoints. Pharmaceutical Statistics, 2012, 11, 118-128.	1.3	32
14	Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial. Breast Cancer Research and Treatment, 2016, 155, 99-107.	2.5	32
15	Effects of lifestyle advice provided by pharmacists on blood pressure: The COMmunity Pharmacists ASSist for Blood Pressure (COMPASS-BP) randomized trial. BioScience Trends, 2017, 11, 632-639.	3.4	28
16	Sample size determination in clinical trials with multiple coâ€primary endpoints including mixed continuous and binary variables. Biometrical Journal, 2012, 54, 716-729.	1.0	27
17	Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes. Statistics in Biopharmaceutical Research, 2015, 7, 36-54.	0.8	27
18	Sample size determination for clinical trials with coâ€primary outcomes: exponential event times. Pharmaceutical Statistics, 2013, 12, 28-34.	1.3	25

Таказні Sozu

#	Article	IF	CITATIONS
19	A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints. Biostatistics, 2013, 14, 409-421.	1.5	24
20	Sample size determination in groupâ€sequential clinical trials with two coâ€primary endpoints. Statistics in Medicine, 2014, 33, 2897-2913.	1.6	24
21	Sense of meaning in work and risk of burnout among medical professionals. Psychiatry and Clinical Neurosciences, 2015, 69, 123-124.	1.8	23
22	Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease. BMJ Open, 2018, 8, e023998.	1.9	23
23	Power and Sample Size Calculations in Clinical Trials with Mutiple Primary Variables. Japanese Journal of Biometrics, 2006, 27, 83-96.	0.0	22
24	An Evaluation of Performance Standards and Non-radioactive Endpoints for the Local Lymph Node Assay. ATLA Alternatives To Laboratory Animals, 2008, 36, 243-257.	1.0	21
25	Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology (TRUTH Study) Rationale and Design. Circulation Journal, 2009, 73, 352-355.	1.6	21
26	Second-phase validation study of short time exposure test for assessment of eye irritation potency of chemicals. Toxicology in Vitro, 2013, 27, 1855-1869.	2.4	21
27	Railway suicide attempts are associated with amount of sunlight in recent days. Journal of Affective Disorders, 2014, 152-154, 162-168.	4.1	18
28	Risk Factors for Progression of Degenerative Aortic Valve Disease in the Japanese – The Japanese Aortic Stenosis Study (JASS) Prospective Analysis –. Circulation Journal, 2015, 79, 2050-2057.	1.6	17
29	Effects of vitamin K antagonist on aortic valve degeneration in non-valvular atrial fibrillation patients: Prospective 4-year observational study. Thrombosis Research, 2017, 160, 69-75.	1.7	16
30	Sample Size Determination in Clinical Trials with Multiple Endpoints. SpringerBriefs in Statistics, 2015,	0.4	15
31	Interlaboratory validation of the modified murine local lymph node assay based on adenosine triphosphate measurement. Journal of Pharmacological and Toxicological Methods, 2008, 58, 11-26.	0.7	13
32	Sizing clinical trials when comparing bivariate timeâ€ŧoâ€event outcomes. Statistics in Medicine, 2017, 36, 1363-1382.	1.6	12
33	Long-term cognitive benefits of donepezil in Alzheimer?s disease: A retrospective comparison between 1994?1999 and 2000?2004. Geriatrics and Gerontology International, 2007, 7, 41-47.	1.5	11
34	Inter-laboratory validation of the modified murine local lymph node assay based on 5-bromo-2′-deoxyuridine incorporation. Journal of Applied Toxicology, 2011, 31, 63-74.	2.8	11
35	Sample Size Considerations in Clinical Trials When Comparing Two Interventions Using Multiple Co-Primary Binary Relative Risk Contrasts. Statistics in Biopharmaceutical Research, 2015, 7, 81-94.	0.8	10
36	How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study. International Journal of Urology, 2006, 13, 127-131.	1.0	9

Таказні Sozu

#	Article	IF	CITATIONS
37	Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study. Journal of Cardiology, 2017, 69, 518-522.	1.9	9
38	The within―and betweenâ€laboratory reproducibility and predictive capacity of the in chemico amino acid derivative reactivity assay: Results of validation study implemented in four participating laboratories. Journal of Applied Toxicology, 2019, 39, 1492-1505.	2.8	9
39	Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel–Haenszel method are recommended. Pharmaceutical Statistics, 2015, 14, 198-204.	1.3	8
40	Second malignancy versus recurrence after complete resection of thymoma. Asian Cardiovascular and Thoracic Annals, 2018, 26, 290-295.	0.5	8
41	Time course of statin-induced changes in coronary atherosclerosis using intravascular ultrasound with virtual histology. Coronary Artery Disease, 2013, 24, 481-486.	0.7	7
42	Group-Sequential Designs When Considering Two Binary Outcomes as Co-Primary Endpoints. ICSA Book Series in Statistics, 2015, , 235-262.	0.2	7
43	C-Reactive Protein and Future Cardiovascular Events in Statin-Treated Patients with Angina Pectoris: The Extended TRUTH Study. Journal of Atherosclerosis and Thrombosis, 2013, 20, 717-725.	2.0	6
44	Prognostic factors of idiopathic inflammatory myopathies complicated with interstitial lung disease: protocol for a systematic review and meta-analysis. BMJ Open, 2016, 6, e012744.	1.9	6
45	Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer. Chemotherapy, 2016, 61, 256-261.	1.6	6
46	Selfâ€efficacy modulates the neural correlates of craving in male smokers and exâ€smokers: an fMRI study. Addiction Biology, 2018, 23, 1179-1188.	2.6	6
47	Primary Endpoints in Current Phase II/III Trials for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2020, 34, 97-100.	1.3	6
48	Estimating the False Discovery Rate Using Mixed Normal Distribution for Identifying Differentially Expressed Genes in Microarray Data Analysis. Cancer Informatics, 2007, 3, 117693510700300.	1.9	5
49	Changes in coronary atherosclerosis, composition, and fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes. IJC Heart and Vasculature, 2018, 19, 46-51.	1.1	5
50	RenalGuard system to prevent contrast-induced acute kidney injury in Japanese patients with renal dysfunction; RESPECT KIDNEY study. Cardiovascular Intervention and Therapeutics, 2019, 34, 105-112.	2.3	5
51	Multi-laboratory Validation Study of the Vitrigel-Eye Irritancy Test Method as an Alternative to In Vivo Eye Irritation Testing. ATLA Alternatives To Laboratory Animals, 2019, 47, 140-157.	1.0	5
52	Risk Factors for Cytarabine-Induced Cutaneous Toxicity in Patients with Haematological Malignancies. Chemotherapy, 2014, 60, 168-173.	1.6	4
53	Reducing unnecessary measurements in clinical trials with multiple primary endpoints. Journal of Biopharmaceutical Statistics, 2016, 26, 631-643.	0.8	4
54	Anterior mediastinal tissue volume is correlated with antiacetylcholine receptor antibody level in myasthenia gravis. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2738-2744.	0.8	4

Takashi Sozu

#	Article	IF	CITATIONS
55	Mortality from extrathymic malignancy after thymic tumour resections: incidences and risk factors. Interactive Cardiovascular and Thoracic Surgery, 2019, 29, 729-736.	1.1	4
56	Longitudinal effects of oneâ€leg standing time on neuropathy outcomes in association with glycemic control in nonâ€elderly patients with type 2 diabetes. Journal of Diabetes Investigation, 2022, 13, 1039-1051	2.4	4
57	Group cognitive behavioural therapy (GCBT) versus treatment as usual (TAU) in the treatment of irritable bowel syndrome (IBS): a study protocol for a randomized controlled trial. BMC Gastroenterology, 2020, 20, 29.	2.0	3
58	Association of One-Leg Standing Time with Discontinuation of Injectable Medications During Hospitalization Among Patients with Type 2 Diabetes. Diabetes Therapy, 2020, 11, 1179-1190.	2.5	3
59	Flexible use of copulaâ€ŧype model for doseâ€finding in drug combination clinical trials. Biometrics, 2022, 78, 1651-1661.	1.4	3
60	Predicting study duration in clinical trials with a timeâ€ŧoâ€event endpoint. Statistics in Medicine, 2021, 40, 2413-2421.	1.6	2
61	The within―and betweenâ€laboratories reproducibility and predictive capacity of Amino acid Derivative Reactivity Assay using 4 mM test chemical solution: Results of ring study implemented at five participating laboratories. Journal of Applied Toxicology, 2022, 42, 318-333.	2.8	2
62	Group Cognitive-Behavioral Therapy With Interoceptive Exposure for Drug-Refractory Irritable Bowel Syndrome: A Randomized Controlled Trial. American Journal of Gastroenterology, 2022, 117, 668-677.	0.4	2
63	A Survey on Introductory Statistics Classes in Japanese Medical Schools. Japanese Journal of Biometrics, 2015, 35, 95-105.	0.0	1
64	Matrix decomposition in metaâ€analysis for extraction of adverse event pattern and patientâ€level safety profile. Pharmaceutical Statistics, 2021, 20, 806-819.	1.3	1
65	A Test for Treatment Effects Based on the Exact Distribution of an Ordinary Least-Square Estimator in Sequential Parallel Comparison Design. Statistics in Biopharmaceutical Research, 0, , 1-10.	0.8	1
66	A Proposal to Improve the Patient Survey Focusing on the Recent Trend of Increase in the Missing Data. Journal of the Japan Statistical Society, 2005, 35, 121-134.	0.1	1
67	Optimal adaptive allocation using deep reinforcement learning in a doseâ€response study. Statistics in Medicine, 2021, , .	1.6	1
68	Within―and betweenâ€laboratory reproducibility and predictive capacity of amino acid derivative reactivity assay (ADRA) using a 0.5 mg/mL test chemical solution: Results of the study for reproducibility confirmation implemented in five participating laboratories. Journal of Applied Toxicology, 2022, , .	2.8	1
69	A hospital-based cross-sectional study to develop an estimation formula for 2-h post-challenge plasma glucose for screening impaired glucose tolerance. Diabetes Research and Clinical Practice, 2013, 101, 218-225.	2.8	0
70	Authors' reply. Biometrical Journal, 2013, 55, 813-813.	1.0	0
71	Statistical Issues in Clinical Trials with Multiple Primary Endpoints. Japanese Journal of Biometrics, 2013, 34, 35-52.	0.0	0
72	Multiplicity Issues in Clinical Trials. Japanese Journal of Biometrics, 2015, 36, S87-S98.	0.0	0

Takashi Sozu

#	Article	IF	CITATIONS
73	Eradication ofHelicobacter pylorifor iron deficiency. The Cochrane Library, 2015, , .	2.8	Ο
74	The preventive approach to degenerative aortic stenosis should depart from the approach to atherosclerotic diseases: A Japanese perspective. European Journal of Preventive Cardiology, 2020, 27, 2170-2172.	1.8	0
75	Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals. Therapeutic Innovation and Regulatory Science, 2020, 54, 1185-1191.	1.6	Ο
76	Improving the Stratification of Medical Institutions for Stratified Sampling in the Patient Survey. Journal of the Japan Statistical Society, 2005, 35, 135-145.	0.1	0
77	Continuous Co-primary Endpoints. SpringerBriefs in Statistics, 2015, , 7-23.	0.4	0
78	Convenient Sample Size Formula. SpringerBriefs in Statistics, 2015, , 41-58.	0.4	0
79	A Survey of Introductory Statistics Courses at Schools of Medicine, Dentistry and Pharmaceutical Sciences in Japan: Does the Cause of Overemphasis on <i>p</i> -values Lie with University Education?. Japanese Journal of Biometrics, 2018, 38, 141-152.	0.0	Ο
80	Sample size determination in phase I oncology trials based on selection probability of the maximum tolerated dose. Japanese Journal of Biometrics, 2021, 42, 55-64.	0.0	0